Eli Lilly (LLY) Goodwill & Intangibles (2009 - 2026)
Eli Lilly (LLY) reported Goodwill & Intangibles of $13.5 billion for Q1 2026, up 14.61% on a YoY basis from $11.8 billion in Q1 2025, and up 8.74% quarter-over-quarter from $12.4 billion in Q4 2025.
Eli Lilly (LLY) Goodwill & Intangibles (2009 - 2026) Analysis & Trends
Eli Lilly has reported Goodwill & Intangibles for 18 years, with the latest figure at $13.5 billion in Q1 2026.
- For the quarter ending Q1 2026, Goodwill & Intangibles rose 14.61% year-over-year to $13.5 billion; the trailing twelve-month figure through Mar 2026 stood at $13.5 billion (up 14.61% YoY), and the FY2025 full-year result was $12.4 billion, up 4.05% from the prior year.
- Goodwill & Intangibles for Q1 2026 stood at $13.5 billion, up from $12.4 billion in the prior quarter.
- The five-year high for Goodwill & Intangibles was $13.5 billion in Q1 2026, with the low at $10.9 billion in Q3 2023.
- Historically, Goodwill & Intangibles has averaged $11.8 billion across 5 years, with a median of $11.7 billion in 2024.
- Annual changes were most pronounced in 2022 — Goodwill & Intangibles slipped 6.42% — and 2026, when it climbed 14.61%.
- Eli Lilly's Goodwill & Intangibles stood at $11.3 billion in 2022, then grew by 5.02% to $11.8 billion in 2023, then grew by 0.76% to $11.9 billion in 2024, then gained by 4.05% to $12.4 billion in 2025, then increased by 8.74% to $13.5 billion in 2026.
- The last three Goodwill & Intangibles figures came in at $13.5 billion (Q1 2026), $12.4 billion (Q4 2025), and $12.3 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn |
| 10 | Novartis Ag | 112.59 Bn | 111.90 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.50 Bn |
| Dec 31, 2025 | 12.42 Bn |
| Sep 30, 2025 | 12.34 Bn |
| Jun 30, 2025 | 11.68 Bn |
| Mar 31, 2025 | 11.78 Bn |
| Dec 31, 2024 | 11.94 Bn |
| Sep 30, 2024 | 12.31 Bn |
| Jun 30, 2024 | 12.40 Bn |
| Mar 31, 2024 | 11.70 Bn |
| Dec 31, 2023 | 11.85 Bn |
| Sep 30, 2023 | 10.87 Bn |
| Jun 30, 2023 | 10.98 Bn |
| Mar 31, 2023 | 11.16 Bn |
| Dec 31, 2022 | 11.28 Bn |
| Sep 30, 2022 | 11.02 Bn |
| Jun 30, 2022 | 11.39 Bn |
| Mar 31, 2022 | 11.37 Bn |
| Dec 31, 2021 | 11.58 Bn |
| Sep 30, 2021 | 11.77 Bn |
| Jun 30, 2021 | 11.87 Bn |